High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC

BACKGROUND: Immune checkpoint inhibitors (ICIs) targeting the programmed cell death 1/programmed death-ligand 1 axis have transformed the management of advanced non-small cell lung cancer (NSCLC). However, many patients do not benefit from this type of treatment, and thus several molecular biomarker...

Descripción completa

Detalles Bibliográficos
Autores principales: Frigola, Joan, Carbonell, Caterina, Iranzo, Patricia, Pardo, Nuria, Callejo, Ana, Cedres, Susana, Martinez-Marti, Alex, Navarro, Alejandro, Soleda, Mireia, Jimenez, Jose, Hernandez-Losa, Javier, Vivancos, Ana, Felip, Enriqueta, Amat, Ramon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047699/
https://www.ncbi.nlm.nih.gov/pubmed/35477861
http://dx.doi.org/10.1136/jitc-2021-004197

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047699/
https://www.ncbi.nlm.nih.gov/pubmed/35477861
http://dx.doi.org/10.1136/jitc-2021-004197

Ejemplares similares